Asthma medication is supposed to help you breathe easier, not make your mind feel like it has been tossed into a blender with the lid off. Yet in recent years, one question has become increasingly important for patients, parents, and clinicians: Can asthma medication be linked to suicidal ideation?
The short answer is: yes, there may be a link with certain asthma medications, especially montelukast, sold under the brand name Singulair and as generics. But the bigger answer is more nuanced. Not every asthma medicine carries the same mental health concern. Inhaled corticosteroids, rescue inhalers, combination inhalers, biologics, and leukotriene modifiers all work differently. The warning that gets the most attention involves montelukast, a leukotriene receptor antagonist used for asthma, exercise-induced bronchoconstriction, and allergic rhinitis.
This does not mean everyone who takes montelukast will experience depression, anxiety, nightmares, mood changes, or suicidal thoughts. Many people take it and do well. But the concern is serious enough that the U.S. Food and Drug Administration requires a boxed warning, the agency’s most prominent safety warning, for montelukast because of possible serious neuropsychiatric side effects, including suicidal thoughts and actions.
If you or someone near you is having suicidal thoughts, call or text 988 in the United States for the Suicide & Crisis Lifeline. If there is immediate danger, call 911 or go to the nearest emergency room. Breathing matters. So does staying alive. Both deserve urgent care.
What asthma medications are we talking about?
Asthma treatment usually falls into two big buckets: quick-relief medicines and long-term control medicines. Quick-relief inhalers, such as albuterol, relax tightened airway muscles during sudden symptoms. Controller medicines, such as inhaled corticosteroids, help calm airway inflammation over time so asthma attacks are less likely to crash the party.
Montelukast belongs to a different group called leukotriene receptor antagonists. Leukotrienes are inflammatory chemicals involved in airway swelling, mucus production, and bronchoconstriction. Montelukast blocks leukotriene activity, which can help reduce asthma symptoms and allergy-related nasal symptoms. It is taken by mouth, often once daily, which makes it appealing for people who dislike inhalers or have trouble using them correctly.
That convenience is part of the reason montelukast became widely prescribed. A pill can feel easier than coordinating an inhaler, spacer, rinse, refill, and the tiny existential crisis that comes from wondering whether you actually inhaled the dose. However, convenience does not erase risk.
The main concern: montelukast and mental health side effects
The strongest safety concern linking asthma medication and suicidal ideation centers on montelukast. Reports submitted to regulators and post-marketing safety monitoring have described mood and behavior changes in some patients taking the drug. These reported effects include anxiety, depression, agitation, irritability, vivid dreams, nightmares, sleep problems, hallucinations, confusion, obsessive-compulsive symptoms, and suicidal thoughts or actions.
Importantly, these symptoms have been reported in adults, adolescents, and children. They have also been reported in people with and without a previous history of mental illness. That last part matters. A patient might think, “I’ve never had depression, so this warning does not apply to me.” Unfortunately, side effects do not always check your resume before showing up.
The FDA strengthened warnings for montelukast in 2020 after reviewing available evidence and concluding that many patients and health care professionals were still not fully aware of the mental health risks. The agency also advised that, for allergic rhinitis, montelukast should generally be reserved for people who cannot tolerate or do not respond well to other allergy treatments. For asthma, clinicians are advised to weigh the benefits and risks carefully before prescribing or continuing it.
Does the warning prove montelukast causes suicidal ideation?
A boxed warning is not the same as saying, “This medication definitely causes suicidal thoughts in every case.” Medicine is rarely that tidy. Human biology is more like a crowded airport than a neat spreadsheet.
Some reports suggest a possible relationship between montelukast and neuropsychiatric symptoms. In many cases, symptoms appeared during treatment and improved after the medication was stopped. In other cases, symptoms continued after stopping, or began after discontinuation. These patterns are concerning, but spontaneous reports cannot always prove causation because they may lack complete information about other medications, underlying conditions, stressors, family history, or timing.
Research findings have been mixed. Some large observational studies have not found a statistically clear increase in overall neuropsychiatric events compared with other asthma medications. For example, a large pediatric cohort study published in 2025 found no overall association between montelukast use and neuropsychiatric adverse events compared with long-acting beta agonists. However, the absence of a broad population-level signal does not mean individual patients cannot experience serious side effects.
That is the practical takeaway: the risk appears uncommon, but it is real enough to take seriously. Patients should not panic, but they should not ignore new mood, sleep, or behavior changes either.
Are inhaled corticosteroids linked to suicidal ideation?
Inhaled corticosteroids are among the most commonly used long-term controller medications for asthma. They reduce airway inflammation and are considered a cornerstone of asthma control for many patients. Examples include budesonide, fluticasone, beclomethasone, and mometasone.
Unlike montelukast, inhaled corticosteroids do not carry the same boxed warning for suicidal ideation. They can have side effects, such as oral thrush, hoarseness, throat irritation, and, at higher doses, possible systemic effects. But the mental health warning conversation around asthma medication is mainly about montelukast and related neuropsychiatric reports, not standard inhaled steroid therapy.
This distinction is important because some people hear “asthma medicine and suicide warning” and assume all asthma medications are suspect. That can lead to dangerous decisions, such as suddenly stopping controller inhalers. Poorly controlled asthma can be life-threatening. If your lungs are already staging a rebellion, removing the peace treaty without medical guidance is not the move.
What symptoms should patients and families watch for?
Anyone taking montelukast should know the warning signs. Patients, parents, partners, roommates, and caregivers should watch for sudden or unusual changes in mood, sleep, thinking, or behavior.
Possible warning signs include:
- New or worsening depression
- Anxiety, panic, or unusual fearfulness
- Agitation, aggression, hostility, or irritability
- Vivid dreams, nightmares, or sleepwalking
- Insomnia or major changes in sleep patterns
- Confusion, disorientation, or memory problems
- Hallucinations or unusual thoughts
- Obsessive thoughts or compulsive behaviors
- Restlessness or tremors
- Suicidal thoughts, self-harm thoughts, or talk of wanting to die
These symptoms can be subtle at first. A child may not say, “I am experiencing neuropsychiatric adverse effects.” A child may say, “I feel weird,” “I can’t sleep,” “I’m scared,” or “I don’t feel like myself.” Adults may notice unusual anger, emotional flatness, racing thoughts, or a sense that their personality has been replaced by a moody raccoon in a hoodie.
If mood or behavior changes appear after starting montelukast, contact the prescribing clinician promptly. If suicidal thoughts or self-harm urges appear, seek emergency help immediately.
Should you stop taking asthma medication?
Do not stop asthma medication casually, especially controller inhalers or rescue inhalers. Asthma can worsen quickly, and uncontrolled asthma can lead to emergency visits, hospitalization, or worse.
Montelukast is different because official patient guidance advises stopping it and contacting a health care professional right away if serious mood or behavior-related symptoms occur. That does not mean you should quietly quit and hope everything works out. The safer plan is to stop only as directed by the warning guidance and immediately involve your clinician so your asthma remains controlled with an alternative treatment plan.
If you are taking montelukast and feel well, do not assume you must stop it today. Instead, have a risk-benefit conversation with your doctor. Ask why you are taking it, whether it is helping, whether alternatives are appropriate, and what warning signs should trigger action.
Who may need extra caution?
Extra caution may be appropriate for patients with a personal or family history of depression, anxiety, bipolar disorder, suicidal ideation, sleep disorders, or severe behavioral changes. But because serious mental health side effects have been reported in people without prior mental health conditions, everyone taking montelukast should receive counseling about the warning.
Parents of children and teens should be especially observant. Children may struggle to describe inner emotional changes. Teens may hide symptoms because they fear being judged, grounded, or dragged into a Very Serious Family Meeting at the kitchen table. A calm, nonjudgmental check-in can help: “Since starting this medicine, have you noticed weird dreams, mood changes, anger, sadness, or thoughts that scare you?”
Adults should also monitor themselves. A simple symptom journal can help. Write down when the medication started, sleep quality, mood, anxiety level, asthma symptoms, and any unusual thoughts. Patterns are easier to spot when they are not floating around in memory like socks in a dryer.
What alternatives may be available?
Alternative asthma treatments depend on the patient’s age, asthma severity, triggers, lung function, allergy profile, and response to previous therapies. For many patients, inhaled corticosteroids are the foundation of long-term control. Some people use combination inhalers that include an inhaled corticosteroid and a long-acting bronchodilator. Others may need add-on therapies such as long-acting muscarinic antagonists or biologic medications for severe asthma.
For allergic rhinitis, alternatives may include antihistamines, steroid nasal sprays, saline rinses, allergen avoidance, or immunotherapy in selected cases. The best choice depends on symptoms and medical history.
The key is not to swap medications like trading cards. Work with a clinician. Asthma treatment should be individualized, adjusted over time, and supported by an asthma action plan. The best medication is not always the newest, strongest, or most convenient. It is the one that controls symptoms with acceptable risk.
How to have a smart conversation with your doctor
If montelukast is part of your asthma or allergy plan, bring specific questions to your appointment. A focused conversation can prevent both overreaction and underreaction.
Questions to ask include:
- Why was montelukast prescribed for me or my child?
- Is it being used for asthma, allergies, exercise-induced symptoms, or more than one condition?
- How will we know if it is helping?
- What mental health symptoms should we watch for?
- What should I do if nightmares, anxiety, depression, or suicidal thoughts appear?
- Are there safer alternatives for my situation?
- Can we create or update my asthma action plan?
Also tell your clinician about any history of depression, anxiety, self-harm, sleep disorders, attention problems, or major recent stress. These details are not embarrassing footnotes. They are useful medical information.
Real-world experiences: what patients and families often describe
Experiences with asthma medication and suicidal ideation vary widely. Some people take montelukast for years and describe it as a quiet hero: fewer nighttime symptoms, better exercise tolerance, less wheezing during allergy season, and no noticeable mental health effects. For these patients, the medication may be part of a successful asthma control plan. They may wonder why the warning receives so much attention when their personal experience has been uneventful.
Other patients tell a very different story. A parent may notice that a normally cheerful child becomes unusually irritable after starting montelukast. At first, the family blames school stress, screen time, poor sleep, or the mysterious emotional weather system known as “being twelve.” Then nightmares begin. The child wakes up scared, becomes clingy, or refuses bedtime. A teenager may become withdrawn, anxious, or suddenly angry. An adult may notice intrusive thoughts, dark moods, or a sense of emotional disconnection that feels completely out of character.
In some experiences, the timeline is the clue. Symptoms may begin days or weeks after starting the medication. Sometimes the connection is missed because asthma itself is stressful. Not breathing well can make anyone anxious. Poor sleep from coughing can turn even a saint into a cranky houseplant. Allergy season can be miserable. Because these factors overlap, patients and families may not immediately suspect a medication side effect.
One practical example: imagine an adult with spring allergies and mild asthma who starts montelukast because sneezing, wheezing, and nighttime coughing are ruining sleep. Two weeks later, the coughing improves, but vivid dreams and morning dread appear. The person feels unusually hopeless and thinks, “This is not me.” That is the moment to contact the prescriber, not the moment to tough it out in heroic silence.
Another example: a child with exercise-induced asthma starts montelukast and performs better at soccer practice. Great! But then the child begins having nightmares and sudden anger outbursts. The family should not automatically conclude the medicine is guilty, but they should consider it as a possible contributor and call the clinician. A good care plan protects both the lungs and the mind.
Some patients also describe relief after stopping montelukast under medical guidance, while others do not notice a change. That variability is exactly why individualized care matters. A medication can be helpful for one person, harmful for another, and unnecessary for a third. Medicine is not one-size-fits-all; it is more like tailoring, except the fabric is biology and the measurements keep changing.
The emotional lesson from these experiences is simple: take patient observations seriously. If someone says, “I feel different since starting this medication,” that deserves attention. It does not prove causation, but it does deserve a respectful medical review. Patients should never be dismissed as dramatic, and parents should not be brushed off as overprotective. Sometimes the person closest to the daily behavior changes sees the pattern first.
Conclusion: is there a link?
There is a recognized safety concern linking montelukast with serious mental health side effects, including suicidal ideation and suicidal actions. The evidence is not perfectly simple, and population studies have produced mixed results, but the risk is serious enough for an FDA boxed warning and careful patient counseling.
The link does not apply equally to every asthma medication. Inhaled corticosteroids, rescue inhalers, and other asthma treatments have different safety profiles. Patients should not abandon asthma control out of fear. Instead, they should understand which medication they are taking, why they are taking it, what benefits it provides, and what side effects require urgent action.
If montelukast is helping and no side effects are present, discuss ongoing use with a clinician. If mood changes, nightmares, depression, agitation, or suicidal thoughts appear, act quickly. Asthma care should help people live fuller lives, not leave them fighting a second battle in silence.
Important safety note: If you or someone else is thinking about self-harm or suicide, call or text 988 in the United States for immediate crisis support. If there is immediate danger, call 911. For medication-related concerns, contact the prescribing health care professional as soon as possible.
